Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaBen add-on treatment for adults with schizophrenia
2017-001169-26Phase 2Unknown
- Sponsor
- SyneuRx
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing NaBen add-on with Placebo add-on (2 arms). Primary endpoint: Mean change from baseline in PANSS total score after 8 weeks of randomized treatment. Status: unknown.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001169-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001169-26.